DelveInsight projects that the Alzheimer’s disease market will undergo rapid evolution over the next decade, driven by rising disease prevalence, growing awareness, and the advancement of a robust clinical pipeline. The anticipated launch of therapies across multiple stages of development is expected to significantly reshape market dynamics during the forecast period.

DelveInsight’s report titled “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2034” provides a detailed assessment of the disease landscape, including historical and projected epidemiology, treatment patterns, and market trends across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The study evaluates current standards of care, emerging therapies, market share by treatment, and market size forecasts from 2020 to 2034, while also analyzing key drivers, challenges, and unmet needs shaping future opportunities in the Alzheimer’s disease space.

Get a Free sample for the Alzheimer’s Disease Market Report:

https://www.delveinsight.com/report-store/alzheimers-disease-ad-market

Key Highlights from the Alzheimer’s Disease Market Report

• The global Alzheimer’s disease market was valued at approximately USD 5,038 million in 2025 and is projected to expand at a robust CAGR of 23.7% through 2034.
• In December 2025, Spinogenix reported early and sustained cognitive benefits for tazbentetol, its oral small-molecule candidate, in a Phase IIa study involving patients with mild-to-moderate Alzheimer’s disease.
• Biogen, in November 2025, announced new data presentations on LEQEMBI® (lecanemab) at the CTAD conference, highlighting subcutaneous dosing, long-term treatment benefits, and real-world evidence from Japan and the ALZ-NET registry.
• Eisai’s etalanetug (E2814), an anti-MTBR tau antibody, received FDA Fast Track designation in September 2025.
• In the same month, Alzinova AB secured FDA IND approval for a Phase II trial of ALZ-101, a vaccine candidate targeting Alzheimer’s disease.
• In August 2025, the FDA approved LEQEMBI IQLIK™, a once-weekly subcutaneous autoinjector formulation of lecanemab, for maintenance therapy in early Alzheimer’s disease.
• Cognition Therapeutics, in July 2025, reported up to a 129% reduction in cognitive decline with zervimesine in a Phase II trial among patients with mild Alzheimer’s disease and lower biomarker burden.
• Roche’s trontinemab demonstrated sustained amyloid clearance and biomarker reductions in an ongoing Phase Ib/IIa study during mid-2025.

Alzheimer’s Disease Epidemiology and Regional Insights

DelveInsight estimates that nearly 16 million diagnosed Alzheimer’s disease cases were reported across the 7MM in 2024. The United States accounted for approximately 44% of these cases, with nearly 7 million patients, a figure expected to rise by 2034.

Age-based segmentation in the US shows the highest prevalence among individuals aged 75–84 years, while severity-based analysis indicates that mild cognitive impairment (MCI) represents the largest patient pool across EU4 and the UK. Gender-based data consistently reveal a higher prevalence among women compared with men, particularly in Japan.

Download the report to understand which factors are driving Alzheimer’s Disease epidemiology trends @ Alzheimer’s Disease Epidemiological Insights

Alzheimer’s Disease Pipeline Landscape and Competitive Environment

The Alzheimer’s disease pipeline is expanding rapidly, with therapies targeting amyloid beta, tau pathology, neuroinflammation, and metabolic dysfunction. Notable late- and mid-stage candidates include LEQEMBI, KISUNLA (donanemab), BAN2401, gantenerumab, ALZT-OP1, and valiltramiprosate.

Leading companies active in the market include Biogen/Eisai, Eli Lilly, Hoffmann-La Roche, Alzheon, AB Science, Cerecin, BioVie, and Neurotrope Bioscience, among others.

Alzheimer’s Disease Market Outlook

The Alzheimer’s disease market is expected to grow substantially over the forecast period, supported by advances in diagnostics, increased healthcare investment, regulatory incentives, and a growing focus on disease-modifying therapies. While challenges such as complex disease biology and high treatment costs remain, the evolving pipeline is poised to redefine treatment paradigms and improve patient outcomes.

Discover more about therapies set to grab major Alzheimer’s Disease market share @ Alzheimer’s Disease Treatment Landscape

About DelveInsight

DelveInsight is a leading healthcare business consulting and market research firm dedicated exclusively to the life sciences sector. The company partners with pharmaceutical and biotech organizations to deliver end-to-end solutions that enhance performance, support strategic decision-making, and drive sustainable business growth through data-driven insights and practical consulting expertise.